SenzaGen receives order for GARD™skin and GARD™potency from a major US chemical company

SenzaGen will assess the skin sensitizing hazards of chemicals for a global chemical company based in the US. The new order, with a value of approximately SEK 0.4 million, includes testing with both GARD™skin and GARD™potency. The unique ability of the GARD technology to assess formulations and determine whether a substance is a weak or strong allergen without animal testing, was key for the order. The tests will be carried out at SenzaGen's laboratory in Lund, Sweden.

With an industry-leading product and technology pipeline, the customer is headquartered in the US and operates globally. Connected to one of the customer’s investigatory projects, this new order follows a successful evaluation of the GARD tests earlier this year.

“I am very pleased about this collaboration and we are looking forward to supporting their safety testing needs now and in the future. The chemical industry as a whole has a great need for safety testing and this project is in line with the customer’s commitment to the 3Rs – reduce, refine and replace animals in toxicology testing. It is with global customer references like this that we build credibility and lay the foundation for future growth”, says Axel Sjöblad, CEO of SenzaGen.

SenzaGen’s test platform GARD provides a highly accurate in vitro method for skin sensitization assessment of chemicals, including formulations, traditionally considered “difficult-to-test” samples. The method targets companies looking to optimize their testing strategy, thus increasing the safety of products while avoiding animal testing.

SenzaGen’s 2020 Half-Year Report: Sales doubled in first half year

Message from the CEO
”Despite operating in a time when the ordering and purchasing processes of our customers have been significantly influenced by COVID-19, our sales increased in the first six months of 2020 to SEK 3.8 million, representing a more than double year-on-year increase and one million higher than our entire 2019 sales. With a focused sales organization and more potential customers evaluating our tests, we are in a great position to continue developing as a commercial enterprise despite the current external challenges. I believe that we have passed the test of transitioning to the "new normal" with flying colors and that we will be able to keep up the same fast pace when working on our strategic initiatives in the fall.”

Axel Sjöblad, CEO

Half year 1 January–30 June

  • Net sales totaled SEK 3.8 (1.7) million.
  • The operating loss was SEK -12.9 (-15.2) million.
  • Earnings per share were SEK -0.60 (-0.97).
  • Cash and cash equivalents at 30 June amounted to SEK 101.5 (41.9) million.

Significant events during the first half year

  • A new global customer ordered tests for a cumulative value of SEK 1.2 million.
  • SenzaGen received an order worth SEK 0.5 million from a world-leading raw material supplier.
  • SenzaGen received GLP approval.
  • SenzaGen and XCellR8 expanded their collaboration to offer GARD®skin Animal Product-Free.
  • SenzaGen and US Research Institute for Fragrance Materials (RIFM) signed a collaboration agreement to develop next-generation tests for photosensitization.

Significant events after the end of the period

  • SenzaGen signed a distribution agreement with Danske Teknologisk Institut (DTI) in Denmark.


Conference call
SenzaGen is pleased to invite press and investors to a conference call on Thursday, August 20 at 9:30 CEST where CEO Axel Sjöblad will comment on SenzaGen’s 2020 half-year results. The conference call, which will be held in English, will begin with a presentation of the report followed by a Q&A session.

Phone number for conference call
To participate in the conference call, use the dial-in numbers below.

SE: +46850558351
FR: +33170750737
DE: +4969222239167
CH: +41225675632
NE: +31107129162
UK: +443333009269

Web link
https://tv.streamfabriken.com/senzagen-q2-2020

Invitation to SenzaGen’s 2020 half year report conference call on Aug 20 at 9.30 CEST

SenzaGen is pleased to invite press and investors to a conference call on Thursday August 20 at 9.30 CEST where CEO Axel Sjöblad comments SenzaGen’s 2020 half year results.

The conference call, which will be held in English, will begin with a presentation of the report followed by a Q&A session.

Phone number for the conference
To participate in the conference call, use the dial-in numbers below.

SE: +46850558351
FR: +33170750737
DE: +4969222239167
CH: +41225675632
NE: +31107129162
UK: +443333009269

Weblink
https://tv.streamfabriken.com/senzagen-q2-2020

SenzaGen signs distributor agreement with the Danish Technological Institute in Denmark

SenzaGen has signed a distributor agreement with the reputable Danish Technological Institute (DTI). DTI holds a strong position as a proponent of new technology towards a large network of global customers, leading research institutes and universities. With this agreement SenzaGen further expand its licensing and distribution network in Europe with a strategically important partner.

The distributor agreement gives DTI the right to market and sell SenzaGen's test platform GARD® to both Danish and global customers in a wide range of industry sectors, including the chemical, pharmaceutical and medical technology industries, who want to increase the accuracy of their test results while avoiding animal studies. The agreement initially runs for 1 year with the possibility of extension.

“DTI holds a leading position in the life science industry in Denmark and the Nordic countries. With its unique position and competence, DTI helps to introduce, apply and disseminate new technology and knowledge into society. DTI has a strong presence in many of the industries that we prioritize, and together with DTI we look forward to introducing the GARD technology to their customers,” says Axel Sjöblad, CEO of SenzaGen.

DTI is an independent research and development institute that develops, applies and disseminates knowledge in the field of research and technology. With more than 10,000 customers in 65 countries and an annual turnover of approximately DKK 1 billion, DTI's experts support and participate in a large number of development projects in close collaboration with R&D establishments and universities around the world. In addition, DTI carries out consultancy services, training, certification, and safety testing in a variety of scientific fields, not the least of which is life sciences. By giving its customers access to the latest technology and knowledge, DTI encourages new innovative ideas and contributes to sustainable solutions.

The reliable GARD assay fits DTI’s mission by improving the quality of customers decision-making and contributing to increased product safety in people’s everyday lives.

“At DTI, we are protective of our position as a leading research institute and are therefore thorough in our selection and evaluation of the scientific methods we apply. With GARD® technology, we strengthen our offering in safety testing and biocompatibility testing with one of the industry's most reliable and accurate in vitro tests for skin and respiratory sensitization," says Sune Dowler Nygaard, Vice President, Life Science at DTI.

SenzaGen receives SEK 0.6 million follow-up order

In February, SenzaGen tested chemicals for a large global company. The same company now orders additional testing for a value of SEK 0.6 million, with the unique GARD™air assay, to analyse whether selected chemical substances can cause allergic reactions in the respiratory tract. The tests will be carried out in SenzaGen's laboratory in Lund.

“I am happy to see that our new sales organization continues to deliver results. To deepen relationships and partnerships with large global customers is essential for us to establish GARD and to grow as a company. The new order is important since it both confirms that the customer is satisfied with our collaboration and that the GARD assays are demanded despite a business climate characterized by COVID-19,” says Axel Sjöblad, CEO of SenzaGen.

The customer is headquartered in Europe where research and development play a central role. With the GARD™air test, the customer can identify substances that can cause allergy in the airways, and use the results for decision making during both product development and production, which contributes to cost savings for the company and safer products to society.

SenzaGen receives GLP approval

SenzaGen, which develops animal-free in vitro safety tests, has received the important GLP approval from Swedac for its laboratory and the use of its test platform GARD™. The internal work began in 2019 and today, May 27, the Company received the GLP approval. This is a substantial regulatory milestone since the GLP status gives SenzaGen access to customers seeking to file their products with regulators such as the Swedish Medical Products Agency or the FDA.

GLP stands for Good Laboratory Practice and is a quality system of requirements and principles to assure the quality of non-clinical safety studies. What constitutes GLP is defined by the OECD for use as a global standard requirement to ensure high-quality and reliable results for product filings and regulatory approval. Swedac, the Swedish national accreditation body, is the authority that has determined that SenzaGen’s lab meets the GLP requirements.

The approval affirms that SenzaGen’s laboratory operations have ensured that studies subject to GLP requirements can be performed with the quality specified by regulators when the study is used as documentation for regulatory purposes.

“The GLP approval is a regulatory milestone and an important part of SenzaGen’s continuing commercialization. This gives us access to a significantly broader group of customers because we can meet both the customer’s internal quality requirements and the regulatory requirements for study data used in product filings. The approval is also positive for the OECD’s ongoing approval process for GARD since Swedac’s decision shows that the method can be used in a lab subject to regulatory monitoring,” says Axel Sjöblad, CEO of SenzaGen.

For more information, please contact:
Axel Sjöblad, CEO, SenzaGen AB
Email:
axel.sjoblad@senzagen.com | Mobile: +46 705 35 93 51

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Mobile: +46 708 20 29 44

About GARD
GARD™ consists of a group of tests for analyzing a chemical’s capacity to trigger an allergic reaction in humans. The tests target companies looking to optimize their testing strategy and increase the accuracy of their test results while avoiding animal testing. With precision and reliability, GARD improves the quality of customers’ decision-making and contributes to increased product safety while reducing the number of animal tests. SenzaGen is the only company at this time that can provide an in vitro test to determine whether a chemical causes respiratory allergies. The Company’s product portfolio consists of tests for skin and respiratory allergies: GARD™skin, GARD™air, GARD™potency and GARD™skin Medical Device.

About SenzaGen AB (publ) 
SenzaGen’s technology enables the replacement of animal testing with genetic testing in test tubes to determine the allergenicity of the chemicals we come in contact with in our everyday lives, such as those in cosmetics, pharmaceuticals, food products and dyes. The Company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. SenzaGen sells its tests directly in Sweden and the US as well as via partners in several other countries. In the coming years, the Company will expand geographically, partner up with more distributors and launch new, unique tests. SenzaGen has its headquarters in Lund, Sweden and a subsidiary in the US. For more information, please visit: www.senzagen.com.   

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399, is the company’s Certified Adviser.

SenzaGen receives SEK 0.5 million order from world-leading ingredient and raw material supplier

SenzaGen will assess the skin sensitizing hazards of chemicals for a global company specialized in ingredients and raw materials for several different industries and markets. The new order, with a value of approximately SEK 0.5 million, includes testing with both GARD™skin and GARD™potency. The unique ability of the GARD technology to both assess “difficult-to-test” chemicals and determine whether a substance is a weak or strong allergen (potency), was crucial for the agreement. The tests will be carried out at SenzaGen's laboratory in Lund.

With a business operating globally, the customer is headquartered in Europe where innovation, research and development have a central role. The collaboration between the two companies started in the beginning of 2020. After a successful completion of the first tests, the collaboration continues with the signing of the new order.

“I am extremely happy about this collaboration. The new order confirms that our work in our prioritized market segments generates results and that our tests meet the needs of the largest and leading players in the market. Once again, the interest in GARD’s unique ability to test “difficult-to-test” chemicals and their potency is confirmed”, says Axel Sjöblad, CEO of SenzaGen.

For more information, please contact:
Axel Sjöblad, CEO, SenzaGen AB
Email:
axel.sjoblad@senzagen.com | Mobile: +46 705 35 93 51

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Mobile: +46 708 20 29 44

About GARD
GARD consists of a group of tests for analyzing chemicals’ ability to start an allergic reaction in humans. The tests are performed on human cells in test tubes (in vitro) in combination with artificial intelligence and targets companies looking to optimize their in vitro testing strategy; increasing the accuracy of their test results while avoiding animal testing. Through its precision and reliability, GARD improves the quality of customers’ decision-making and contributes to increased product safety in people’s everyday lives while reducing the number of animal experiments. SenzaGen is the only company that can offer a non-animal, so called in vitro test, for chemical respiratory allergens. The product portfolio consists of tests for skin and respiratory allergy: GARD™skin, GARD™air, GARD™potency and GARD™skin Medical Device.

About SenzaGen AB (publ)
SenzaGen’s technology enables replacement of animal experiments with genetic testing in test tubes for determining the allergenicity of the chemicals we come into contact with in our daily lives, such as those in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. SenzaGen sells direct and through partners. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in the US. For more information, please visit www.senzagen.com.

SenzaGen AB is listed on Nasdaq First North in Stockholm (ticker: SENZA) and FNCA Sweden AB, +46(0)8-528 00 399 info@fnca.se, is the company’s Certified Adviser.

SenzaGen and the Research Institute for Fragrance Materials (RIFM) collaborate to develop next-generation test for photosensitization

SenzaGen has entered into collaboration with the Research Institute for Fragrance Materials (RIFM). The collaboration means that SenzaGen, with the support of a RIFM grant, will test several substances for RIFM to assess whether some fragrance materials could cause skin allergies when exposed to sunlight, so-called photosensitization. The cooperation agreement runs through 2021.

RIFM is an international scientific organization working to promote the safe use of fragrance ingredients in consumer products. Part of RIFM's business is promoting the development of new and innovative tests for safety and sensitivity and today there are few reliable alternatives to animal testing. SenzaGen and RIFM have entered a collaboration to further develop and extend the applicability of GARD™skin to include photosensitization. GARDskin is SenzaGen's animal-free assay for assessing substances for potential allergic reactions on skin. The technology adaptation is in line with SenzaGen's strategy to meet more customer needs by optimizing and expanding its product offering.

“RIFM is a world-leading organization for research on fragrances and we are very proud of their confidence in us. The collaboration with RIFM provides a stimulating exchange of knowledge and an opportunity for us to further develop and test GARDskin in an application to assess fragrances for potential skin sensitization when exposed to sunlight. The need for measuring photosensitization risk is significant for, for example, product development companies in the cosmetics and chemicals industry, which are two of our target industries,” says Axel Sjöblad, CEO of SenzaGen.

The two organizations look forward to jointly contributing to a sustainable and ethical development of the testing market.

“Identifying the photosensitization risk of fragrance ingredients with high accuracy is a need that fragrance stakeholders have long expressed. We support SenzaGen's investment in modern technologies and animal-alternative test methods, with the goal that RIFM will be able to use new approach methodologies without compromising scientific quality,” says RIFM’s Gretchen Ritacco, Principal Scientist, Phototoxicology.

For more information, please contact:
Axel Sjöblad, CEO, SenzaGen AB
Email:
axel.sjoblad@senzagen.com | Mobile: +46 705-35 93 51

Gretchen Ritacco, Principal Scientist, Phototoxicology
Email: gritacco@rifm.org | Phone: +1 201.689.8089 ext. 153

About RIFM
Established in 1966, the Research Institute for Fragrance Materials (RIFM) generates, analyzes, evaluates, and distributes data to provide a scientific basis for the safe use of fragrances. RIFM has compiled the most comprehensive, worldwide source of toxicology data, literature, and general information on fragrance and flavor raw materials. RIFM’s fragrance ingredient safety assessment program draws from its comprehensive database of over 70,000 references and more than 135,000 human health and environmental studies.

RIFM assesses the safety of fragrance ingredients by the most current, internationally accepted guidelines—and has done so since its founding. The Expert Panel for Fragrance Safety, an independent, international team of researchers and academics with no ties to the fragrance industry, reviews all of RIFM’s work before RIFM submits it for peer-reviewed publication in a reputable scientific journal. RIFM makes all of its published, peer-reviewed work—current and historical—available for free at fragrancematerialsafetyresource.elsevier.com.

About GARD
GARD consists of a group of tests for analyzing chemicals’ ability to start an allergic reaction in humans. The tests are performed on human cells in test tubes (in vitro) in combination with artificial intelligence and targets companies looking to optimize their in vitro testing strategy; increasing the accuracy of their test results while avoiding animal testing. Through its precision and reliability, GARD improves the quality of customers’ decision-making and contributes to increased product safety in people’s everyday lives while reducing the number of animal experiments. SenzaGen is the only company that can offer a non-animal, so called in vitro test, for chemical respiratory allergens. The product portfolio consists of tests for skin and respiratory allergy: GARD™skin, GARD™air, GARD™potency and GARD™skin Medical Device.

About SenzaGen AB (publ)
SenzaGen’s technology enables replacement of animal experiments with genetic testing in test tubes for determining the allergenicity of the chemicals we come into contact with in our daily lives, such as those in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. SenzaGen sells direct and through partners. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in the US. For more information, please visit www.senzagen.com.

SenzaGen AB is listed on Nasdaq First North in Stockholm (ticker: SENZA) and FNCA Sweden AB, +46(0)8-528 00 399 info@fnca.se, is the company’s Certified Adviser.

SenzaGen and XCellR8 expand their collaboration to offer GARD[®]skin Animal Product-Free

SenzaGen, a Swedish developer of animal-free in vitro tests for sensitization and the British contract testing laboratory, XCellR8, have deepened and expanded their collaboration by signing an exclusive global licensing agreement. The new agreement covers the performance, marketing and sales of SenzaGen's new, vegan skin sensitization test, GARD[®]skin Animal Product-Free.

XCellR8 is an established in vitro contract testing laboratory in Europe engaged in work to replace animal testing and related animal components with alternative methods, especially in the cosmetics industry. Today, XCellR8 works with several well-known cosmetics companies such as The Body Shop, Lush, and their suppliers. SenzaGen and XCellR8 have been in partnership since 2016 through a distribution agreement. Thanks to this new enhanced license agreement, XCellR8 will market and sell GARD®skin Animal Product-Free and perform tests at its laboratory in Daresbury, UK.

“We are happy to deepen our collaboration with Dr. Carol Treasure and her team at XCellR8. By focusing on the use of the latest technology and new research results, they are contributing to the movement towards a more ethical and sustainable testing industry. Our collaboration has resulted in further development of an existing test, adding an offering to our portfolio, which is in line with our strategy and mission to offer the best animal-free test methods,” says Axel Sjöblad, CEO of SenzaGen.

GARD®skin Animal Product-Free is a further development of SenzaGen's existing skin sensitization test, GARD®skin, and meets consumers' growing demand for an animal-free supply chain. By replacing animal serum, traditionally used as a nutrient solution in cell culture, with human serum, this new test is totally free of animal components. GARD®skin Animal Product-Free has the same high accuracy and performance as the other tests available in SenzaGen's portfolio.

“Together with our clients, we are passionate about the vision of creating a more ethical testing industry, without animal testing and animal components. Through this close collaboration with SenzaGen, XCellR8 has the exclusive opportunity to offer this accurate and innovative GARD test, free of animal components, for skin sensitization. In the long term, this means safer and better products for all of us,” says Carol Treasure, founder and CEO of XCellR8.

For more information, please contact:
Axel Sjöblad, CEO, SenzaGen AB
Email: axel.sjoblad@senzagen.com | Mobile: +46 705-35 93 51

Carol Treasure, Founder and CEO, XCellR8
Email:
carol.treasure@x-cellr8.com | Mobile: +44 7899 845222

About XCellR8
XCellR8 provides animal-free safety and efficacy tests to the cosmetics, personal care and chemical industries. Regulatory tests include assessments for skin or eye irritation, skin sensitization and skin corrosion whilst non regulatory tests include cytotoxicity and acute toxicity amongst others. Clients include ingredient manufacturers such as Croda and Innospec, as well as high street retailers both in the UK and globally, including Lush and The Body Shop. Their work has been recognised at a regulatory level by the OECD and the European Chemicals Agency (ECHA), and supported by top funding bodies such as Innovate UK and the European Horizon 2020 programme.

About GARD
GARD consists of a group of tests for analyzing chemicals’ ability to start an allergic reaction in humans. The tests are performed on human cells in test tubes (in vitro) in combination with artificial intelligence and targets companies looking to optimize their in vitro testing strategy; increasing the accuracy of their test results while avoiding animal testing. Through its precision and reliability, GARD improves the quality of customers’ decision-making and contributes to increased product safety in people’s everyday lives while reducing the number of animal experiments. SenzaGen is the only company that can offer a non-animal, so called in vitro test, for chemical respiratory allergens. The product portfolio consists of tests for skin and respiratory allergy: GARD™skin, GARD™air, GARD™potency and GARD™skin Medical Device.

About SenzaGen AB (publ)
SenzaGen’s technology enables replacement of animal experiments with genetic testing in test tubes for determining the allergenicity of the chemicals we come into contact with in our daily lives, such as those in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. SenzaGen sells direct in Sweden and the US, and through partners in several other countries. Over the next few years the company will grow geographically, make alliances with additional distribution and license partners, and launch new unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in the US. For more information, please visit www.senzagen.com.

SenzaGen AB is listed on Nasdaq First North in Stockholm (ticker: SENZA) and FNCA Sweden AB, +46(0)8-528 00 399 info@fnca.se, is the company’s Certified Adviser.

SenzaGen: Invitation to full year 2019 conference call on Feb 13 at 9.30 CET

SenzaGen is pleased to invite press and investors to a conference call on Thursday February 13 at 9.30 CET where CEO Axel Sjöblad comments SenzaGen’s 2019 full year results.

The conference call, which will be held in English, will begin with a presentation of the report followed by a Q&A session.

Phone number for the conference:
To participate in the conference call, use the dial-in numbers below.

SE: +46856642695
CH: +41225805976
FR: +33170750718
DE: +4969222220380
NE: +31207219496
UK: +443333009034

Weblink
https://tv.streamfabriken.com/senzagen-full-year-2019

For more information, please contact:
Axel Sjöblad, CEO, SenzaGen AB
Email:
axel.sjoblad@senzagen.com | Mobile: +46 705-35 93 51

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Mobile: +46 708-20 29 44

About GARD™
GARD consists of a group of tests for analyzing chemicals’ ability to start an allergic reaction in humans. The tests are performed on human cells in test tubes (in vitro) in combination with artificial intelligence. By analyzing hundreds of markers, GARD generates large amounts of data and delivers results with over 90 percent accuracy. This can be compared to today’s standard method – tests on animals – which only achieves 70-75 percent accuracy. The product portfolio consists of tests for skin and respiratory allergy: GARD™skin, GARD™air, GARD™potency and GARD™skin Medical Device.

About SenzaGen AB (publ)
SenzaGen’s technology enables replacement of animal experiments with genetic testing in test tubes for determining the allergenicity of the chemicals we come into contact with in our daily lives, such as those in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. SenzaGen sells direct in Sweden and the US, and through partners in several other countries. Over the next few years the company will grow geographically, make alliances with additional distribution and license partners, and launch new unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in the US. For more information, please visit www.senzagen.com.

SenzaGen AB is listed on Nasdaq First North in Stockholm (ticker: SENZA) and FNCA Sweden AB, +46(0)8-528 00 399 info@fnca.se, is the company’s Certified Adviser.